Since 2023, pharmaceutical companies have been raising and investing news
.
In the first week of the new year, pharmaceutical companies such as Lukang Pharmaceutical, Borui Pharmaceutical, Frontier Biotechnology, Jichuan Pharmaceutical, Guangshengtang, Shangkang Pharmaceutical, and Guochuang Pharmaceutical have announced the progress of fundraising and investment projects, and in the past week, a number of pharmaceutical companies have issued fundraising and investment-related announcements
.
For example, on January 13, the company plans to raise 1.
279 billion yuan after the IPO of Xintong Drug Science and Technology Innovation Board, of which 900 million yuan will be used for new drug research and development projects, 180 million yuan will be used for innovative drug industrialization production base construction projects, and 200 million yuan will be used for supplementary working capital projects
.
According to the data, Xintong Drug is a company focusing on drug research and development, now focusing on chronic hepatitis B, liver cancer, epilepsy and other major diseases, one of the core products, CE-fosphenytoin sodium injection, has submitted a marketing authorization application in July 2021, the product is used to treat systemic tonic-clonic status epilepticus, prevent and treat neurosurgical perioperative and surgical seizures
.
For example, recently, Bibet Pharma submitted a prospectus to be listed
on the Science and Technology Innovation Board.
The company plans to raise 2 billion yuan this time, of which 950 million yuan will be used for new drug research and development projects, 555 million yuan will be used for Qingyuan R&D center and preparation industrialization base construction projects, and 500 million yuan will be used to supplement working capital
.
According to the data, Bibet Pharmaceutical is a biopharmaceutical enterprise guided by clinical value and focusing on the independent research and development of innovative drugs
.
The company focuses on major diseases such as tumors, autoimmune diseases, and metabolic diseases, and continues to develop global first-in-class and innovative drugs
that do not meet clinical needs by relying on the core technology platform built by independent research and development.
Judging from the situation of pharmaceutical companies that have announced fundraising and investment projects since 2023, the funds raised by these pharmaceutical companies mainly focus on project areas
such as new drug research and development.
Behind this phenomenon, it can be seen that pharmaceutical companies are optimistic about the prospects of innovative drugs
.
The research and development of innovative drugs has the characteristics of long payback period and high input cost, and requires capital support
.
In the territory of innovative drugs, the Science and Technology Innovation Board is another major listing place
for Biotech after NASDAQ and the Hong Kong Stock Exchange.
According to industry statistics, in the first half of 2022, 8 Biotechs were listed on the Science and Technology Innovation Board according to the fifth set of standards, which has surpassed the 4 18A listed companies
in Hong Kong stocks in the same period.
Up to now, there are 23 innovative pharmaceutical companies listed on the STAR Market, raising a total of 66.
452 billion yuan in IPOs, including 18 innovative pharmaceutical companies listed according to the fifth set of standards, as well as two red-chip companies
BeiGene and InnoCare.
For domestic innovative drugs, the progress of the industry in recent years is obvious to all, the strength of domestic innovative drug companies is constantly improving, with the acceleration of new drug approval and review, pharmaceutical companies increase R&D investment, innovative achievements will continue to enter the harvest period, benefiting the vast number of patient groups
.
However, it should also be recognized that compared with multinational pharmaceutical companies, there is still a gap
in the level of innovation and R&D of local pharmaceutical companies.
At present, the phenomenon of domestic listed products is more serious, and even many products under research are similar, in this regard, the industry believes that the height and intensity of innovation of local pharmaceutical companies need to be strengthened, and it is necessary to accelerate the transformation
from metoo and fastfollow to FIC.
The huge population base, coupled with the aging trend of the population and the upgrading of consumption levels, has driven the domestic innovative drug market to maintain a sustained and rapid growth momentum, and the size of China's innovative drug market reached US$153.
8 billion in 2021, a year-on-year increase of 8.
46%, and it is expected that by 2024, this market size is expected to exceed US$200 billion
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
